Doximity: How Physicians Became the Audience
The Attention Arbitrage
Every morning, approximately 640,000 American physicians open an application that knows their specialty, their prescribing habits, their hospital affiliation, and their daily schedule. They do not pay for the privilege. They check medical news, sign documents, message colleagues, and increasingly, dictate patient notes through an <a href="https://bangid.com/industry/health-and-life-sciences/” target=”_blank” rel=”noopener”>AI scribe that learns their cadence. The platform serves them one advertisement for every eleven pieces of content, recisely targeted, measurement-verified, and worth far more than the banner ads that clutter consumer internet backwaters. This is Doximity: a business built on the strange economics of professional attention, where the users are not the customers, and the customers are not permitted to disturb the users too much.
The model operates on a simple inversion. Where most professional software extracts value directly from its users through subscriptions or licenses, Doximity extracts value from pharmaceutical companies by selling access to those users, while keeping the users themselves in a state of subsidized contentment. The arithmetic is stark. Gross margins hover at ninety percent. EBITDA margins exceed fifty-five percent. Capital expenditures consume barely one percent of revenue. The business generates approximately $900 million in net cash, roughly $5 per share, while funding an expanding suite of workflow tools that cost nearly nothing to distribute to an already-captured audience.
This is not merely a media business dressed in scrubs. It is a compounding engine where engagement creates inventory, inventory funds research and development, and R&D produces tools that deepen engagement. Pharmaceutical advertisers, operating in a $7 billion direct-to-physician market that still lags other industries in digital penetration, pay premiums for precision that traditional sales representatives cannot match. A cardiovascular drugmaker can target interventional cardiologists in specific zip codes, then measure whether those doctors actually prescribed the drug through third-party pharmacy data. The platform captures roughly eighty percent of U.S. doctors, creating a liquidity advantage that competitors cannot replicate without simultaneously rebuilding both supply (physician adoption) and demand (advertiser confidence in return on investment). The resulting moat is structural: high switching costs embedded in daily workflow habits, reinforced by network effects that make the platform more valuable as more colleagues join.
Yet the engine runs on a fuel that is volatile and politically exposed: the discretionary advertising budgets of pharmaceutical companies. When drug makers face margin compression from price caps, tariffs, or regulatory action, the $7 billion pool of direct-to-physician marketing represents the first expenditure cut. Unlike enterprise software that becomes embedded in hospital operating budgets, these are marketing dollars, allocated quarterly based on ROI. The business model depends on the secular belief that pharma will continue shifting spend from traditional sales reps and print journals toward digital channels at a sustained five-to-seven percent annual clip, and that Doximity will capture not just the growth, but the consolidation, oving from ten percent to over fifty percent of major brand budgets. If that consolidation slows while the underlying market remains modest, the company faces a deceleration cliff that no amount of product innovation can offset.
The Constraint of Gratitude
The most consequential strategic decision Doximity makes is what it chooses not to charge for. The platform offers digital signature capabilities, HIPAA-compliant messaging, telehealth infrastructure, and increasingly sophisticated AI-powered clinical tools including automated scribing and differential diagnosis assistance. All are free to the physician. This is not generosity; it is a binding constraint. Charging doctors, even for high-value AI features that demonstrably reduce documentation burden, risks disengagement, and disengagement collapses the advertising inventory that constitutes the entirety of revenue.
This creates a peculiar tension at the heart of the enterprise. The company develops tools that could command premium subscription fees in any other context. AI scribing alone represents a potential billion-dollar SaaS market when sold separately. Yet Doximity must treat these innovations as loss leaders, deploying them to increase time-on-platform and daily active usage metrics that translate into ad impressions. The “doctor-first” philosophy, often discussed in mission-driven terms, functions as an economic necessity. Physicians tolerate the advertising precisely because they do not pay for the utility. Introducing a paywall, even for advanced features, would transform the psychological contract from gratitude to transactional evaluation, inviting users to compare Doximity’s AI scribe against Nuance’s or Amboss’s clinical reference against UpToDate’s. Once doctors become customers, they become critics, and critics churn.
The constraint shapes every product decision. The advertising load remains deliberately light, one ad per eleven news items, because heavy advertising would violate the doctor-first covenant and trigger exodus. Product development prioritizes integration over excellence in any single vertical. The messaging function need not surpass WhatsApp; the newsfeed need not compete with Medscape for depth; the scribing need not match dedicated point solutions for accuracy. It must only be good enough to prevent fragmentation, to keep the physician within the garden walls for as long as possible each day. The platform’s value proposition is not superiority but continuity, the reduction of friction between tasks that otherwise require separate logins, separate interfaces, separate learning curves.
This constraint also explains the company’s resistance to enterprise sales. Hospital systems control access, budgets, and procurement decisions for most healthcare technology. They prefer vendor consolidation, standardized contracts, and administrative oversight. Doximity could pivot toward lucrative enterprise agreements, selling its platform to health systems as a bundled productivity suite. But such a shift would transfer power from individual physicians to hospital administrators, who might demand customization, limit pharmaceutical access, or negotiate down the margin structure that makes the business viable. By remaining doctor-centric, bypassing the IT procurement committees and appealing directly to users, Doximity preserves the high-margin advertising model. The strategy treats physicians as sovereign agents rather than hospital employees, a positioning that builds loyalty but leaves the company vulnerable if health systems ever consolidate their influence over professional software choices.
The Architecture of Impossible Margins
Most analyses of Doximity focus on its network effects or its pharma relationships, but the underappreciated structural advantage lies in its cost architecture. Ninety percent gross margins combined with one percent capital expenditure requirements create a reinvestment dynamic that competitors cannot replicate. When a traditional SaaS company earns revenue, it must spend heavily on sales and marketing to acquire the next customer, and significantly on infrastructure to serve them. Doximity’s incremental cost of delivering an additional ad impression to an already-engaged physician approaches zero. The marginal user generates revenue without proportional cost; the marginal advertiser pays for inventory that requires no additional server farms or sales teams to maintain.
This margin structure functions as a defensive weapon. Every dollar of profit can be deployed into R&D, xpanding the <a href="https://bangid.com/industry/health-and-life-sciences/” target=”_blank” rel=”noopener”>AI scribe, improving the telehealth interface, adding continuing medical education credits, ithout diluting profitability. Competitors attempting to enter the space face a cruel mathematics. If they choose a subscription model to serve doctors, they bear the high customer acquisition costs and churn risks endemic to healthcare SaaS, while lacking the advertising revenue to fund rapid product expansion. If they attempt to copy Doximity’s ad-supported model, they must simultaneously attract a critical mass of physicians to interest pharma advertisers, while attracting advertisers to fund physician tools: chicken-and-egg problem requiring years of capital burn at negative margins.
The balance sheet reinforces this advantage. With $900 million in net cash and minimal ongoing capital requirements, Doximity can acquire nascent AI companies or telehealth features not for revenue, but for engagement, dding tools that would bankrupt smaller competitors who need to charge for them. The company can afford to be patient, to optimize for daily active users rather than quarterly recurring revenue, because its unit economics do not depend on extraction from the user base. This creates a compounding loop: higher engagement funds better tools, which drive higher engagement, which creates more ad inventory, which funds better tools. The loop continues until a competitor can match the margin profile, which would require simultaneously achieving Doximity’s scale, advertiser relationships, and cost structure: feat that grows more expensive and difficult as the platform expands.
When Transparency Bites Back
In late 2023, Doximity launched “the Portal,” a real-time dashboard allowing pharmaceutical advertisers to measure the performance of their campaigns against actual prescription data. The tool represented a significant technical and commercial advancement, providing granular ROI visibility that traditional sales rep interactions or journal advertising could never offer. Pharma marketers could see not just impressions and clicks, but whether their messaging correlated with changed prescribing behavior among targeted specialists. The Portal accelerated the secular shift of advertising budgets onto the platform, validating Doximity’s core value proposition: here, unlike elsewhere, marketing spend produces measurable returns.
Yet the Portal introduces a subtle strategic tension that may erode long-term pricing power. By providing perfect transparency into advertising effectiveness, Doximity enables sophisticated price optimization. Advertisers can now calculate exactly what a specialist impression is worth to them based on prescription lift data. In the short term, this transparency drives wallet share consolidation, rands shift budgets from opaque channels to measurable ones. But over time, as pharma marketing departments grow accustomed to granular performance data, they gain leverage to negotiate rates based on demonstrated ROI. The platform risks commoditizing its own inventory, transforming from a premium, relationship-based advertising channel into a commodity exchange where buyers optimize spend algorithmically.
The tension mirrors the broader platform dilemma of the 2020s: providing data that proves value initially locks in customers, but eventually trains them to demand efficiency. If Doximity’s targeting remains demonstrably superior to alternatives, pharma advertisers will pay the premium. But if competitors emerge with comparable measurement capabilities, or if the Portal’s data reveals that certain specialties or messaging strategies underperform, advertisers gain the ammunition to demand price concessions. The transparency that built the moat may eventually breach the walls. The company must balance the Portal’s adoption-driving clarity against the opacity that preserves premium pricing, a calibration that grows more delicate as Doximity approaches saturation of the large-brand advertising market.
The Mediocre Excellence
The most fragile assumption underlying Doximity’s valuation is that physicians will continue accepting “good enough” across multiple workflows rather than fragmenting to specialized tools that excel in single verticals. The platform currently offers competent messaging, adequate telehealth, functional digital signing, and increasingly capable but not exceptional AI scribing. It assumes that the convenience of integration, the elimination of context-switching between six different applications, outweighs the benefits of using the absolute best tool for each specific task. This assumption holds true only as long as the point solutions remain marginally better, not categorically superior.
The risk crystallizes in the current AI wave. Dedicated clinical scribing companies, ambient listening technologies that parse patient encounters with high fidelity, are improving rapidly. Clinical reference tools like Amboss or VisualDx offer diagnostic depth that Doximity’s generalist AI cannot match. If a point solution emerges that is not just better but transformative, reducing documentation time by fifty percent rather than fifteen, or preventing diagnostic errors at rates that affect malpractice premiums, the integrated platform model fractures. Physicians, despite the friction of managing multiple logins, will defect for tools that materially alter their daily practice or legal exposure.
Doximity’s defense against fragmentation depends on velocity. The margin architecture allows the company to acquire or build features fast enough to keep the gap between “good enough” and “best-in-class” narrow. But it cannot win every vertical. In clinical reference, UpToDate retains authority. In secure messaging, native hospital systems or Epic’s integration threaten stickiness. The platform wins not by superiority but by sufficiency across the widest possible surface area. This is a precarious equilibrium. It requires that no single workflow becomes so technically demanding or legally sensitive that only a specialized tool can satisfy it. Should AI scribing, for instance, become a regulated medical device requiring FDA validation and specialty-specific training, Doximity’s generalist approach may prove inadequate, pushing doctors toward compliant point solutions while Doximity retains only the low-value messaging and news functions.
The Enterprise Shadow
Beneath the doctor-first rhetoric lies a latent power struggle with hospital systems that could restructure the entire business. Currently, Doximity markets directly to physicians, bypassing the enterprise procurement processes that dominate healthcare technology. This direct-to-user approach preserves the advertising model because hospitals, if they controlled the platform, would likely restrict pharmaceutical messaging, demand revenue-sharing, or insist on subscription pricing that aligns with their budget cycles rather than Doximity’s ad-supported margins.
However, as hospital systems consolidate and as value-based care pressures mount, administrators increasingly seek to control the digital tools their physicians use. They want data on physician productivity, standardized communication channels, and reduced vendor fragmentation. If a major health system, say, HCA or Kaiser, decided to block Doximity at the firewall or negotiate an enterprise license that stripped out pharmaceutical advertising, the platform would face a existential choice: abandon the high-margin ad model to retain access, or lose access to thousands of physicians who cannot use the platform at work.
The doctor-first philosophy, while building user loyalty, leaves Doximity politically exposed in these negotiations. The company has no enterprise sales infrastructure to speak of, no Chief Medical Information Officer outreach program, no proof of ROI for hospital operations. It sells to doctors; hospitals tolerate it because doctors demand it. But tolerance is not strategy. As health systems deploy their own secure messaging, their own <a href="https://bangid.com/industry/health-and-life-sciences/” target=”_blank” rel=”noopener”>AI scribes, their own physician portals, Doximity’s independence becomes a vulnerability. The platform depends on physicians remaining individual economic actors, free to choose their own tools. If employment models shift further toward corporate practice, if hospitals assert property rights over physician workflow data, the advertising business faces structural pressure to convert into a low-margin enterprise SaaS vendor: transformation that would destroy the margin profile and the investment thesis simultaneously.
The Last Percent
The secular growth narrative relies on two concurrent engines: the digital shift within the $7 billion direct-to-physician advertising market, growing five-to-seven percent annually, and Doximity’s capture of an increasing share of major pharmaceutical brand budgets. The first engine is demographic and technological, inevitable but modest. The second is zero-sum, a consolidation of wallet share that has already moved from ten percent to over fifty percent for large brands. When the consolidation engine stalls, when Doximity has captured all the spend that pharma is willing to move from sales reps to digital, the company must rely solely on the modest growth of the underlying market.
This creates a saturation cliff visible in the model’s mathematics. If Doximity reaches seventy or eighty percent wallet share among major brands, the remaining twenty percent represents the most resistant segments: drugs requiring high-touch educational detailing, therapies where personal relationships dominate prescribing decisions, or conservative marketing departments wedded to traditional channels. Capturing this last increment becomes exponentially more expensive in terms of product development and sales effort. Meanwhile, the underlying market growth of five-to-seven percent, while steady, does not justify the valuation multiples implied by the current consolidation trajectory.
The company’s response, expanding into hospital marketing, recruitment advertising, or international markets, requires capabilities and margin structures different from the core business. Hospital marketing involves different buyers and longer sales cycles. Recruitment competes with LinkedIn and specialty boards. International expansion faces regulatory complexity around pharmaceutical advertising that the U.S. model avoids. The current growth appears robust because it draws from two sources: market expansion and share theft. As the second source depletes, the business must prove it can thrive as a mature, slow-growing utility rather than a high-growth consolidator. The transition from growth to value, from share capture to market maintenance, tests whether the “good enough” platform can retain engagement without the constant innovation funded by hypergrowth, and whether pharma advertisers remain loyal when the platform no longer offers expanding reach but merely stable impressions.
Doximity stands at the intersection of two irresistible forces: the digitization of professional life and the quantification of marketing ROI. It has built a rare business where users and customers are distinct, where margins expand with scale, and where daily habit formation creates defensive moats. Yet it operates under constraints that leave little room for error. It cannot charge its users. It cannot alienate them with excessive advertising. It cannot afford to lag in any workflow category by a margin wide enough to trigger fragmentation. And it cannot transform into an enterprise vendor without destroying the economics that make it valuable. The platform succeeds as long as physicians wake each morning and choose convenience over perfection, as long as pharmaceutical companies value measurement over margin, and as long as hospitals remain hands-off landlords of their physicians’ digital lives. That equilibrium is profitable, but it is not permanent. The business is an arbitrage of attention sustained by structural economics, vulnerable to the moment when doctors, advertisers, or institutions decide the trade is no longer fair.
The arbitrage depends on a specific calibration of irritation. Physicians accept the presence of pharmaceutical messaging because it remains peripheral to their workflow, a background hum rather than an interruption. The one-in-eleven ratio of ads to content in the newsfeed represents not a marketing decision but a finely tuned equilibrium. Increase the density to one-in-five, and the platform transforms from a professional utility into an advertising vehicle; decrease it to one-in-twenty, and revenue suffocates. This balance is precarious because the boundary between “targeted information” and “manipulation” shifts with cultural and regulatory winds.
Consider the mechanics of what Doximity actually sells. Pharmaceutical companies pay to place messages that appear alongside clinical news and continuing medical education. These messages are targeted using self-identified specialty data and refined through prescription tracking that matches ad exposure to pharmacy claims. A doctor views an advertisement for a new diabetes therapeutic; three months later, data brokers confirm whether that doctor wrote prescriptions for the drug. This closed-loop measurement is the platform’s core value proposition, but it exists in a regulatory gray zone that combines medical privacy, commercial speech, and pharmaceutical marketing regulations.
The fragility becomes apparent when tracing the chain of data custody. Doximity does not directly handle prescription data, that resides with pharmacies and data aggregators like IQVIA, but the platform facilitates the matching of identity graphs across these boundaries. A physician’s professional profile, their engagement with specific clinical content, and their subsequent prescribing behavior become linked in ways that would alarm patients if described on a consent form. While currently compliant with HIPAA and FDA guidelines regarding direct-to-physician marketing, the model depends on a specific interpretation of “educational content” versus “promotional material.” If regulatory scrutiny increases, f the FDA determines that AI-targeted messaging constitutes amplified promotion requiring stricter adverse event reporting, or if Congress investigates whether such precise targeting contributes to overprescribing: he compliance costs could escalate rapidly.
The reputational risk runs parallel. Physicians join the platform under the impression that they are receiving professional tools and curated news. The revelation that their engagement patterns, reading habits, and clinical interests are being packaged into precision-targeting profiles for pharmaceutical sales forces could trigger a backlash that no product feature could mitigate. This is distinct from consumer social media, where users generally understand that they are the product. Doctors operate under different ethical expectations. The white coat carries with it an assumption of professional autonomy; learning that one’s prescribing behavior is being monitored and monetized in real-time could violate the psychological contract that keeps them engaged.
The Portal exacerbates this exposure. By providing pharmaceutical marketers with granular ROI data, Doximity has made the surveillance explicit. Advertisers now know exactly which messages moved prescribing needles among which specialties. This transparency, while commercially powerful, creates a paper trail. If a future investigation links targeted Doximity campaigns to inappropriate prescribing, opioid overuse, off-label promotion of psychiatric medications, or the encouragement of expensive brand-name drugs over effective generics, the platform could face liability as an enabler. The company would argue that it merely provides the channel, not the content, but courts and regulators have historically been unsympathetic to such distinctions when technology platforms facilitate harmful outcomes.
The AI tools introduce additional vectors for disengagement. Doximity has deployed ambient scribing technology that listens to patient encounters and generates clinical notes. The feature reduces documentation burden, but it also introduces medical-legal risk. If the AI misinterprets a critical symptom, omits a medication allergy, or generates a note that suggests a standard of care not actually provided, liability attaches not just to the physician but potentially to the platform that provided the tool. Unlike Epic or Cerner, which operate under extensive hospital indemnification agreements, Doximity’s direct-to-physician model leaves the company exposed to malpractice claims that could prove existential.
The accuracy threshold for clinical AI is unforgiving. A consumer application can hallucinate travel recommendations or restaurant reviews without consequence; a clinical tool that fabricates a lab value or confuses “hypo” with “hyper” in a thyroid discussion creates patient harm. As Doximity expands its AI offerings from scribing into differential diagnosis and clinical reference, it moves from administrative convenience into clinical decision support: regulated category requiring rigorous validation. The company must maintain “good enough” accuracy across dozens of specialties without the institutional infrastructure of traditional medical publishers. A high-profile error, an AI-generated recommendation that leads to a missed cancer diagnosis, could trigger not just litigation but a wholesale exodus of risk-averse physicians who cannot afford the liability of using unproven tools, regardless of their convenience.
The cultural dimension of the company functions as an economic variable often overlooked in spreadsheet analysis. Doximity was founded by physicians and maintains a “doctor-first” ethos that manifests in product decisions, hiring, and strategic prioritization. This is not mere branding; it shapes capital allocation in ways that directly affect returns. When choosing between maximizing ad load and preserving user experience, the culture dictates the latter. When deciding whether to sell physician data to third parties for secondary uses, the culture prevents it. This governance model, privileging professional relationships over quarterly revenue optimization, has preserved the platform’s integrity but also leaves money on the table.
Competitors without such cultural constraints could theoretically out-monetize Doximity by selling deeper data insights or accepting higher ad densities, though they would risk the user base. The doctor-first philosophy acts as a commitment device, a costly signal that keeps physicians loyal even as the platform commercializes their attention. However, this culture creates blind spots regarding enterprise sales and hospital system negotiations. The leadership’s reluctance to build traditional vendor management relationships, fearing the bureaucratization of the user experience, means the company enters potential partnership discussions from a position of weakness. When a health system demands customization, integration with specific electronic health records, or administrative oversight of physician usage, Doximity’s cultural instinct is to decline rather than adapt. This preserves margins but limits optionality.
The cash position, nearly $900 million, represents both a strategic asset and a governance challenge. With minimal capital requirements and prodigious free cash flow, the company faces the classic conglomerate dilemma: how to deploy surplus capital without diluting the core model. Acquisitions of point-solution competitors risk integration failures and cultural clashes. Share buybacks signal maturity and potentially arrest growth narratives. International expansion requires navigating pharmaceutical advertising regulations that vary dramatically from the American context. In many European markets, direct-to-physician advertising of prescription drugs is severely restricted or prohibited, eliminating the core revenue model. In emerging markets, physician density and digital adoption may not support the advertising economics.
The capital allocation decisions reveal the company’s theory of its own durability. If management believes the moat is narrow and timing limited, they should maximize cash extraction through buybacks and dividends. If they believe the platform can expand into adjacent healthcare workflows, billing, prior authorization, specialist referrals, they should invest aggressively in product development despite the margin compression. Current strategy suggests a middle path: selective acquisitions of AI capabilities, modest international experimentation, and significant buybacks that suggest confidence in the current model’s longevity but uncertainty about expansion vectors.
The specific mechanics of the pharmaceutical advertising market deserve closer examination. The $7 billion direct-to-physician budget splits unevenly between “reach and frequency” brand campaigns and “conversion-focused” messaging for specific therapeutic switches. Doximity has captured the latter category almost entirely; the Portal’s ROI measurement is overkill for brand awareness but essential for conversion. However, the conversion-focused segment is cyclical and vulnerable to patent cliffs. When a major blockbuster loses exclusivity, the marketing budget supporting that specific therapeutic class evaporates. The platform must constantly acquire new drug launches to replace expiring campaigns, a treadmill that requires maintaining relationships with dozens of pharmaceutical marketing departments.
The sales force dynamics within pharma create additional concentration risk. Unlike enterprise software with annual contracts, pharmaceutical advertising budgets shift quarterly based on clinical trial results, FDA approvals, and competitive launches. A single failed Phase III trial can eliminate a $50 million campaign overnight. Doximity’s revenue concentration among the largest pharmaceutical brands, those spending over $100 million annually, means that the loss of two or three major accounts creates visible deceleration. The platform mitigates this through breadth, serving hundreds of brands across therapeutic areas, but the top twenty likely represent a disproportionate share of revenue.
The “good enough” product strategy faces its most severe test in the current generative AI wave. Previous technology cycles moved slowly enough that Doximity could acquire or build functional equivalents to point solutions before they achieved critical mass. The current pace of AI development compresses these timelines. A startup launched today with superior clinical reasoning capabilities could reach a million physicians before Doximity’s next product cycle completes. The switching costs that protect the platform assume moderate pace; they may not hold against discontinuities.
Consider the specific threat of ambient clinical intelligence. Nuance, now owned by Microsoft, integrates deeply with Epic and offers scribing capabilities tied directly to the electronic health record. If Nuance achieves seamless workflow integration that eliminates the friction of copying notes between platforms, Doximity’s standalone scribe becomes redundant regardless of its individual merit. Similarly, if OpenAI or Google develop medical large language models that hospitals can deploy directly into their existing infrastructure, the “platform” advantage of Doximity’s integrated suite diminishes. The company bets that physicians will prefer a single interface for news, messaging, and documentation over best-in-class individual tools. This bet assumes that hospital IT departments remain permissive, allowing unsanctioned applications on clinical workstations. That permissiveness is already eroding as cybersecurity concerns mount.
The cybersecurity dimension remains underexplored in most analyses. Doximity handles protected health information across messaging, telehealth, and now AI scribing. A significant data breach, patient records exposed through a vulnerability in the telehealth infrastructure, or AI training data leaking sensitive clinical details, would trigger HIPAA penalties and irreversible reputational damage. The platform’s architecture, distributed across millions of individual physician devices rather than centralized in hospital data centers, creates a broad attack surface. Each doctor’s smartphone becomes a potential entry point. The company’s minimal capital expenditure profile, while wonderful for margins, raises questions about security investment relative to the sensitivity of the data handled.
The governance structure ultimately determines how these risks are weighted. As a public company, Doximity faces quarterly pressure to demonstrate growth, yet its doctor-first culture resists the optimization tactics that would maximize short-term revenue. This tension plays out in subtle ways: the pace of ad load increases, the willingness to experiment with subscription tiers for premium AI features, the aggressiveness of international expansion. If leadership changes, if a new CEO arrives from traditional enterprise software with experience in hospital sales, the cultural guardrails might loosen. The resulting revenue optimization could accelerate short-term performance while destroying the trust-based equilibrium that makes the model viable.
The platform’s long-term viability depends on maintaining a paradox: it must be essential enough that physicians cannot leave, yet neutral enough that they do not feel exploited. It must provide pharmaceutical advertisers with precise measurement, yet retain pricing power despite that transparency. It must integrate workflows sufficiently to prevent fragmentation, yet remain technically current as individual tools advance. These balancing acts are not static achievements but continuous negotiations. The structural economics, ninety percent gross margins, fifty-five percent EBITDA, one percent capital intensity, create the buffer necessary to navigate these negotiations, but they do not eliminate the existential nature of the choices. Each product decision, each pricing negotiation with pharma, each response to a hospital system’s integration request, tips the scales toward either the user or the customer, toward consolidation or fragmentation, toward growth or extraction.
Doximity has built a business that should not exist according to traditional software economics: a high-margin, low-churn platform that serves its users without charging them, funded by advertisers who pay premium rates for access to a captive professional class. The model works as long as the captivity remains voluntary, the premiums justified by measurement, and the access unobtrusive. When any of these conditions fail, when doctors feel surveilled rather than served, when pharma measures diminishing returns, when hospitals assert control, the arbitrage collapses. The company trades at a multiple that assumes perpetual expansion of this delicate equilibrium, yet the physics of attention economics suggest that equilibrium is temporary. All platforms eventually face the choice between growth and respect; Doximity has postponed that choice longer than most, but the bill accrues daily.